Motion-aware radiation sharpens cancer treatment for veterinary patients: full analysis

Motion-aware radiation therapy is gaining traction in veterinary oncology as clinicians and researchers work to solve one of radiation medicine’s oldest technical problems: tumors move when patients breathe. In dogs and cats, that motion can be especially challenging during stereotactic treatments, where high doses are delivered in a small number of fractions and precision matters. Newer workflows built around respiratory-gated cone beam CT and other motion-management tools aim to capture that movement more accurately, so radiation can be shaped more tightly around the tumor and away from healthy tissue. That fits naturally with how veterinary radiation is already delivered: treatment planning usually begins with a CT scan under anesthesia to define the full extent of disease, and each treatment session also typically requires anesthesia so the patient stays perfectly still. (acvr-website.s3.amazonaws.com, petmd.com)

That push builds on a broader shift already underway in veterinary radiation oncology. Over the past decade, more specialty hospitals and academic centers have adopted stereotactic radiation therapy, cone beam CT guidance, and upgraded linear accelerators. The field has also become more explicit about reporting standards and treatment precision, reflecting a growing expectation that veterinary radiation planning should mirror the rigor seen in human oncology. A recent systematic review noted the increasing use of stereotactic techniques in dogs and cats, while facility directories from the Veterinary Cancer Society show that respiratory gating is available at at least some specialty centers, though it is still far from universal. Access remains uneven for more basic reasons too: many clinics do not offer radiation at all, which can leave owners facing referral travel, prolonged stays, and substantial cost before advanced motion-management even enters the conversation. (pubmed.ncbi.nlm.nih.gov, petmd.com)

The technical rationale is strong. In an ACVR proceedings abstract focused on respiratory gating in dogs receiving radiation therapy, investigators reported that organ and gross tumor motion depended heavily on tumor location, with structures near the diaphragm moving far more than those in the cranial thorax. In that report, gross tumor volume moved by 2 to 4 mm, and some organs near the diaphragm shifted by 1 to 2 cm with respiration. The authors concluded that respiratory gating can improve margin expansion accuracy and support more precise radiation delivery, potentially allowing dose escalation without increasing risk to organs at risk. Commercial veterinary-capable systems are now advertising 4D CBCT and improved onboard imaging for exactly this use case: reviewing target motion on the table before beam-on. That matters most when clinicians are trying to safely use stereotactic protocols, which concentrate larger doses into fewer fractions rather than the 15 to 21 sessions more typical of conventional fractionated radiation. (acvr-website.s3.amazonaws.com, petmd.com)

That matters because veterinary radiation already delivers meaningful benefit in selected cancers, but the balance between efficacy and toxicity is always case-dependent. The MSD Veterinary Manual notes that radiation therapy should be prescribed and delivered under the supervision of a veterinarian with specialized radiation oncology training, underscoring the complexity of these cases. For canine primary lung tumors, stereotactic radiotherapy has emerged as a non-surgical option, and one retrospective study reported a median survival time of 343 days in dogs treated with SBRT. At the same time, not every veterinary radiation center is equipped to safely treat lung tumors, according to North Carolina State University’s radiation oncology service, which highlights the technical demands of thoracic SRT. Pet-facing guidance also underscores the practical tradeoffs behind those decisions: radiation may be used alone or alongside surgery or chemotherapy, can improve quality of life and occasionally be curative, but repeated anesthesia and treatment-related side effects remain real considerations. PetMD reports that roughly 25% to 50% of dogs experience side effects such as skin irritation, hair loss, or localized inflammation. (msdvetmanual.com, petmd.com)

Industry and academic signals suggest the infrastructure is improving. Cornell said in 2025 that its new Varian Edge linear accelerator allows clinicians to sculpt dose more precisely around normal tissues and reduce side effects compared with older systems. Varian’s veterinary materials likewise emphasize onboard imaging, iterative CBCT, and optional 4D CBCT for motion review immediately before treatment. Those are product-level claims rather than comparative clinical outcomes, but they align with the direction of travel in both human and veterinary radiation oncology: better imaging, smaller margins, and more confidence in where the target actually is at the moment of treatment. If that translates into more safe use of short-course stereotactic protocols, it could also ease some of the access burdens owners face by reducing the number of anesthetized visits compared with conventional fractionation. (vet.cornell.edu, petmd.com)

The comparative oncology angle is also important. Reviews in translational radiation research argue that pet dogs with naturally occurring cancers offer a more clinically relevant bridge than traditional laboratory models for studying imaging, radiobiology, normal tissue effects, and new treatment strategies. That’s part of why motion-aware veterinary radiation is drawing attention beyond animal health alone. If clinicians can characterize respiratory motion, gating thresholds, and dose effects in real-world canine patients, those findings may inform both veterinary protocols and human radiation research. That translational framing is consistent with the Vet Candy source’s emphasis on collaboration between veterinary and human radiation oncology experts. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, motion-aware radiation therapy is less about flashy hardware than about practical control of uncertainty. Better motion characterization could help radiation oncologists reduce planning target margins in selected cases, spare nearby organs, and decide more confidently when a thoracic or abdominal case is appropriate for stereotactic treatment. It could also improve communication with pet parents about expected benefits and tradeoffs, especially when discussing anesthesia, side effects, treatment frequency, referral travel, and whether a case is better served at a center with advanced image guidance. As more hospitals upgrade equipment, the differentiator may become not just whether a center has a linac, but whether it has the imaging workflow, physics support, and case selection discipline to use motion-aware tools well. (acvr-website.s3.amazonaws.com, petmd.com)

What to watch: The next step is stronger published evidence. Watch for peer-reviewed veterinary studies that move beyond feasibility and conference abstracts to report local control, toxicity, workflow burden, and case-selection criteria for gated treatments, especially in lung and other tumors near the diaphragm. Also watch whether more academic and private referral centers add respiratory gating and 4D imaging, which would signal that motion-aware radiation is becoming a standard capability rather than a niche research tool. Just as important, watch whether those advances translate into tangible owner-facing benefits: fewer treatment visits, manageable side-effect profiles, and broader access despite the persistent barriers of cost, travel, and repeated anesthesia. (acvr-website.s3.amazonaws.com, petmd.com)